Supplementary table 1: Correlation between Harvey-Bradshaw index and CRP/markers

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | CRP | C3M | ProC3 | C3M/PRO-C3 | C4M | PRO-C4 | C4M/PRO-C4 |
| IFX HBI baseline | Correlation Coefficient | -0.156 | 0.392 | 0.029 | 0.358 | -0.32 | 0.148 | -0.583 |
|  | *P* value | 0.647 | 0.233 | 0.933 | 0.279 | 0.337 | 0.664 | 0.06 |
| IFX HBI week 14 | Correlation Coefficient | 0.058 | 0.417 | 0.428 | 0.019 | 0.292 | 0.192 | -0.237 |
|   | *P* value | 0.824 | 0.096 | 0.087 | 0.943 | 0.256 | 0.46 | 0.36 |
| ADA HBI baseline | Correlation Coefficient | 0.029 | -0.11 | -0.005 | -0.113 | -0.245 | 0.047 | 0.027 |
|  | *P* value | 0.899 | 0.643 | 0.985 | 0.634 | 0.298 | 0.844 | 0.912 |
| ADA HBI week 8 | Correlation Coefficient | 0.305 | 0.398 | 0.224 | 0.385 | 0.419 | 0.35 | -0.188 |
|  | *P* value | 0.205 | 0.102 | 0.372 | 0.114 | 0.083 | 0.154 | 0.456 |

IFX: infliximab, ADA: adalimumab

Supplementary table 2: Correlation between CRP and Harvey-Bradshaw index/markers

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | HBI | C3M | PRO-C3 | C3M/PRO-C3 | C4M | PRO-C4 | C4M/PRO-C4 |
| IFX CRP baseline | Correlation Coefficient | -0.156 | .671\*\* | 0.044 | 0.455 | .668\*\* | .791\*\* | -0.179 |
|  | *P* value | 0.647 | 0.002 | 0.863 | 0.058 | 0.002 | <0.001 | 0.478 |
| IFX CRP week 14 | Correlation Coefficient | 0.058 | -0.104 | -.596\* | 0.376 | 0.048 | -0.041 | -0.013 |
|  | *P* value | 0.824 | 0.691 | 0.012 | 0.137 | 0.854 | 0.877 | 0.961 |
| ADA CRP baseline | Correlation Coefficient | 0.029 | 0.02 | 0.189 | -0.02 | -0.009 | -0.054 | 0.084 |
|  | *P* value | 0.899 | 0.935 | 0.424 | 0.935 | 0.97 | 0.821 | 0.732 |
| ADA CRP week 8 | Correlation Coefficient | 0.305 | .568\* | -.516\* | .702\*\* | .539\* | 0.326 | 0.096 |
|  | *P* value | 0.205 | 0.014 | 0.028 | 0.001 | 0.021 | 0.187 | 0.704 |

 IFX: infliximab, ADA: adalimumab